Pandemic watch: The biggest COVID-19 news in cardiology, all in one place

In addition to these latest findings, a NIH-backed panel is now specifically recommending against the combination of hydroxychloroquine and azithromycin for treating COVID-19 patients.

Hospitalized COVID-19 patients experience a high rate of thromboembolic complications, according to new findings published in Thrombosis Research.

The high mortality rates from COVID-19 among black patients and other racial/ethnic minorities put a much-needed spotlight on the “deep-rooted failures” of the U.S. healthcare system to improve care for cardiovascular disease (CVD), according to a new commentary.

One side effect of this unprecedented time is that many fourth-year medical students are being asked to join the pandemic’s front lines before they have even graduated.

Researchers have launched a new multi-center clinical trial aimed at learning more about how various blood pressure medications impact the health of patients with COVID-19.   

Researchers examining chloroquine (CQ), an antimalarial medication often suggested as a potential treatment for COVID-19, ended their study early over fears that patients were at an increased risk of significant heart complications.

CMS has announced that healthcare providers in communities experiencing low numbers of confirmed COVID-19 cases may be able to once again provide more in-person care unrelated to the virus.

Cardiologs has announced the beginning of a new clinical trial that will involve monitoring the cardiac health of COVID-19 patients being treated with hydroxychloroquine and azithromycin.

The American Medical Association (AMA) has published new guidelines to help physicians provide care during the ongoing COVID-19 pandemic.

The COVID-19 pandemic has changed patient care in countless ways, but percutaneous coronary intervention (PCI) remains the recommended standard of care for ST-segment elevation myocardial infarction (STEMI) patients.